Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

[The treatment of benign prostatic hyperplasia using the Mumie-Vitas preparation].

Andriukhova NN.

Lik Sprava. 1997 Nov-Dec;(6):129-32. Russian.

PMID:
9589956
2.

Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.

Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S.

J Urol. 2010 Mar;183(3):1092-7. doi: 10.1016/j.juro.2009.11.014. Epub 2010 Jan 25.

PMID:
20092847
3.
4.

[5-alpha-reductase inhibitors in benign prostatic hyperplasia].

Panchev P, Neĭkov K.

Khirurgiia (Sofiia). 1997;50(1):41-3. Bulgarian.

PMID:
9379618
5.

Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.

Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S.

J Urol. 2013 Jan;189(1 Suppl):S135-40. doi: 10.1016/j.juro.2012.11.025.

PMID:
23234619
6.

Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.

Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H.

Neurourol Urodyn. 2013 Nov;32(8):1123-7. doi: 10.1002/nau.22349. Epub 2013 Jul 17.

PMID:
23861329
7.

Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.

Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R.

J Urol. 2009 Dec;182(6):2831-5. doi: 10.1016/j.juro.2009.08.030. Epub 2009 Oct 17.

PMID:
19837428
9.

[Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy].

Sonoda T, Endo H, Maru A, Sasaki K, Kuroda K, Takamura T, Inada F, Rokuzyo M, Ohori T, Kubo T, et al.

Hinyokika Kiyo. 1985 Mar;31(3):553-62. Japanese.

10.

Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: a multicenter, randomized, parallel-group study.

Seki N, Takahashi R, Yamaguchi A, Ito K, Takayama K, Nanri K, Kamiryo Y, Yamashita H, Komine S, Miyazaki Y, Uozumi J, Naito S.

Int J Urol. 2015 Mar;22(3):311-6. doi: 10.1111/iju.12680. Epub 2015 Jan 18.

11.

Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia.

Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K.

Eur Urol. 2008 Aug;54(2):419-26. doi: 10.1016/j.eururo.2008.02.017. Epub 2008 Feb 25.

PMID:
18325657
12.
13.

[Benign prostatic hyperplasia--its treatment with Proscar].

Panchev P, Neĭkov K, Simeonov P.

Khirurgiia (Sofiia). 1996;49(1):15-8. Bulgarian.

PMID:
8975081
14.

[The treatment of patients with benign prostatic hyperplasia with Proscar MSD (finasteride)].

Stepanov VN, Teodorovich OV, Seregin AV, Kadyrov ZA.

Urol Nefrol (Mosk). 1995 Sep-Oct;(5):28-30. Russian.

PMID:
8571480
16.

[The use of drug vitaprost forte in patients with benign prostate hyperplasia].

Neĭmark BA, Neĭmark AI, Nozdrachev NA.

Urologiia. 2013 Jan-Feb;(1):54-6. Russian.

PMID:
23662497
17.

Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.

de Kort LM, Kok ET, Jonges TN, Rosier PF, Bosch JL.

Urology. 2012 Oct;80(4):889-93. doi: 10.1016/j.urology.2012.06.004. Epub 2012 Jul 31.

PMID:
22854138
19.

Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.

Tanaka Y, Masumori N, Itoh N, Sato Y, Takahashi A, Ogura H, Furuya S, Tsukamoto T.

J Urol. 2002 Jun;167(6):2492-5.

PMID:
11992065
20.

Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.

Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K.

Neurourol Urodyn. 2010 Apr;29(4):558-62. doi: 10.1002/nau.20802.

PMID:
19693954

Supplemental Content

Support Center